Clinical Trials Browser

Active not recruiting × INDUSTRY × venetoclax × Clear all

NCT03462719 2026-03-12

GLOW

Phase 3 Active not recruiting

211 enrolled 23 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05453903 2026-03-12

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03844048 2026-03-06

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04623541 2026-03-04

EPCORE™ CLL-1

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT06073821 2026-03-04

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06524375 2026-02-25

BRAVE

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05428969 2026-02-20

BEXMAB

Phase 1/2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT05057494 2026-02-18

MAJIC

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT04965493 2026-01-29

BRUIN CLL-322

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05001828 2026-01-21

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05951959 2025-10-21

TrAVeRse

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT04102020 2025-08-20

VIALE-M

Phase 3 Active not recruiting

112 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

Phase 3 Active not recruiting

443 enrolled 14 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04086264 2025-08-14

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05144243 2025-08-12

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Phase 4 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02942290 2025-08-05

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04603001 2025-06-27

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT04150887 2025-04-17

ELEVATE

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03836261 2024-12-27

AMPLIFY

Phase 3 Active not recruiting

984 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell